在印度治疗高血压的双重疗法的比较:一项随机临床试验
Dorairaj Prabhakaran1, Ambuj Roy2, Ambalam M Chandrasekaran3
1Centre for Chronic Disease Control, New Delhi, India. dprabhakaran@ccdcindia.org.
Nature medicine
|July 27, 2025
概括
三种常见的高血压疗法在南亚患者中表现出同等的有效性和安全性. 阿姆洛迪平-百因多普利尔,百因多普利尔-因达巴胺和阿姆洛迪平-因达巴胺都显著降低了血压 (BP),并实现了高控制率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在南亚人群中缺乏最佳的组合高血压治疗证据.
- 高血压在南亚是一个重大的公共卫生问题.
研究的目的:
- 调查印度患者三种常见的抗高血压双组合药物降血压 (BP) 的有效性和安全性.
- 为了比较阿姆洛迪平 - 佩林多普里尔,佩林多普里尔 - 印帕米德和阿姆洛迪平 - 印帕米德单片组合.
主要方法:
- 一个多中心,单盲随机试验,涉及1981名印度成年人 (30-79岁) 患有高血压.
- 参与者被随机分配给接受安洛迪平 - 佩林多普里尔,佩林多普里尔 - 印帕米德或安洛迪平 - 印帕米德单片组合.
- 主要结局是6个月后24小时门诊系统血压 (SBP) 的平均变化.
主要成果:
- 三种药物组合均显示,在6个月后,24小时的门诊血压 (大约14/8 mmHg) 和办公室血压 (大约30/14 mmHg) 显著降低.
- 在所有三组中,大约70%的参与者实现了高血压控制率 (坐着血压<140/90 mmHg).
- 在二次结果中没有发现显著差异,包括平均白天/夜间门诊和办公室BP,或两组之间的高血压控制率.
结论:
- 阿姆洛迪平 - 佩林多普里尔,佩林多普里尔 - 印帕米德和阿姆洛迪平 - 印帕米德单片组合在降低印度患者的血压方面同样有效和耐受.
- 这些发现为南亚人口的最佳高血压管理提供了宝贵的指导.
相关概念视频
Hypertension IV: Drug Therapy and Lifestyle Modifications
37
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
37
Hypertension III: Clinical Manifestations and Diagnostic Studies
48
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Hypertension and Regulation of Blood Pressure
3.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.1K
Hypertension II: Pathophysiology
73
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
73
Hypertension I: Introduction
71
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
71
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223


